Calixar, a biotechnology company with ten years expertise in the isolation of fully native membrane proteins, is to makes a EUR1 million (USD1.2 million) investment in a new pipeline of complex therapeutic targets and native antigens of high relevance for pharmaceutical companies
This strategic investment, supported by Bpifrance investment bank, will enable the company to be the exclusive provider and licensor for pharmaceutical companies, with the best native and functional membrane therapeutic targets (GPCRs, ion channels, transporters, receptors and viral targets). It will also help them to discover the best drugs (small molecules and conformational antibodies) and develop the best vaccines.
Drug development is becoming more costly and uncertain than ever (over USD1 billion – EUR0.9 billion – in 2020, with a 95 per cent failure rate). Only a few of the drugs authorised each year bring real health benefits. This is despite major scientific advances and ever-increasing investment, with over USD150 billion (EUR139 billion) invested annually worldwide (source: EvaluatePharma).
Calixar was founded in 2011 with the aim of responding to those industry needs. It has developed its own unique technology, together with a research platform, in order to produce high-quality native membrane therapeutic targets that cover all therapeutic areas.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.